Headlines about Biohaven Pharmaceutical (NYSE:BHVN) have been trending positive this week, Accern reports. The research group scores the sentiment of news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Biohaven Pharmaceutical earned a coverage optimism score of 0.26 on Accern’s scale. Accern also gave news stories about the company an impact score of 45.5609858236703 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Here are some of the media headlines that may have impacted Accern’s analysis:
- Implied Volatility Surging for Biohaven Pharmaceutical (BHVN) Stock Options (finance.yahoo.com)
- Biohaven Restructures License Agreement With Bristol-Myers Squib – KAIT Jonesboro, AR – Region 8 News, weather, sports (kait8.com)
- -$0.87 EPS Expected for Biohaven Pharmaceutical Holding Co Ltd (BHVN) This Quarter (americanbankingnews.com)
- Biohaven Pharmaceutical (BHVN) Upgraded by Zacks Investment Research to Buy (americanbankingnews.com)
- Biohaven Pharmaceutical Holding Co Ltd (BHVN) Expected to Earn Q1 2018 Earnings of ($0.69) Per Share (americanbankingnews.com)
Biohaven Pharmaceutical (NYSE BHVN) traded down $0.39 during mid-day trading on Wednesday, reaching $28.54. The company’s stock had a trading volume of 293,000 shares, compared to its average volume of 447,524. Biohaven Pharmaceutical has a 1-year low of $17.00 and a 1-year high of $39.51.
In other news, CFO James Engelhart sold 10,000 shares of the stock in a transaction that occurred on Monday, January 22nd. The stock was sold at an average price of $32.50, for a total transaction of $325,000.00. Following the completion of the transaction, the chief financial officer now directly owns 13,576 shares in the company, valued at approximately $441,220. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Kimberly Gentile sold 5,000 shares of the stock in a transaction that occurred on Thursday, March 1st. The shares were sold at an average price of $32.87, for a total value of $164,350.00. The disclosure for this sale can be found here. Insiders sold a total of 802,976 shares of company stock valued at $22,953,575 over the last 90 days.
Biohaven Pharmaceutical Company Profile
Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.
Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.